Albany Molecular Research Inc
AMRI
AMRI was delisted on the 31st of August, 2017.
139 hedge funds and large institutions have $443M invested in Albany Molecular Research Inc in 2017 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 49 increasing their positions, 45 reducing their positions, and 11 closing their positions.
100% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 11
5% more funds holding
Funds holding: 133 → 139 (+6)
9% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 45
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
24% less capital invested
Capital invested by funds: $581M → $443M (-$137M)
98% less call options, than puts
Call options by funds: $1.15M | Put options by funds: $67.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$65.3M |
| 2 |
ACM
American Capital Management
New York
|
+$12.7M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$11.4M |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$6.9M |
| 5 |
FHAM
Folger Hill Asset Management
New York
|
+$3.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
-$39.1M |
| 2 |
Natixis Advisors
Boston,
Massachusetts
|
-$3.61M |
| 3 |
Renaissance Technologies
New York
|
-$3.43M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$3.03M |
| 5 |
PIP
Permian Investment Partners
Dallas,
Texas
|
-$2.58M |
AMRI Hedge Fund Activity: Q1 2017 in Review
139 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q1 2017, worth a combined $443M — down 24% from $581M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AMRI positions and 11 closed out — a net gain of 11 holders — while 49 added to existing stakes and 45 trimmed.
The largest buyer was BlackRock, adding an estimated $65.3M. The largest seller was Vaughan Nelson Investment Management, exiting entirely with an estimated $39.1M sold.
- 139 institutional investors held Albany Molecular Research Inc (AMRI) as of Q1 2017, up from 133 in Q4 2016.
- Funds reported $443M of Albany Molecular Research Inc stock for Q1 2017, down 24% quarter-over-quarter.
- 22 funds opened new Albany Molecular Research Inc positions in Q1 2017 and 11 closed out, a net change of +11 holders.
- The largest Albany Molecular Research Inc buyer in Q1 2017 was BlackRock, an estimated $65.3M added.
- The largest Albany Molecular Research Inc seller in Q1 2017 was Vaughan Nelson Investment Management, an estimated $39.1M sold.
Based on aggregated 13F filings for Q1 2017.